Every material Form 8-K Edwards Lifesciences filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, representing a 10.5% increase compared to the prior year. Driven by strong procedure volumes and robust performance across its businesses, the company raised its full-year 2026 sales growth and adjusted EPS guidance.
Q3 sales grew 10.5% to $1.72 billion, with constant currency sales up 11.2%.
Q3 EPS was $0.53, while adjusted EPS reached $0.80, up 19% versus the prior year.
Full-year 2026 sales growth guidance was increased to approximately 11.5% from the previous 10% to 11% range.
Adjusted EPS guidance for 2026 was raised to a range of $2.97 to $3.05.
Edwards Lifesciences said Donald E. Bobo, Jr., its Corporate Vice President, Strategy and Corporate Development, will retire by mid-year 2027. The company will begin searching for a successor, with the transition expected during 2027. Mr. Bobo is expected to stay on as a consultant through the end of 2027.
Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, will retire by mid-year 2027
A selection process for a successor begins promptly; the transition of duties is expected during 2027
Mr. Bobo is expected to remain as a consultant through the end of 2027
Edwards Lifesciences reported second-quarter 2026 sales of $1.74 billion, up 13.6% from a year earlier, and raised its full-year 2026 sales growth guidance to 10% to 11% on a constant currency basis. GAAP diluted EPS fell to $0.42 from $0.56 because of a $188.2 million tax valuation allowance tied to California budget legislation, while adjusted EPS rose to $0.78 from $0.67 and full-year adjusted EPS guidance of $2.95 to $3.05 was reaffirmed.
Q2 2026 net sales were $1.74 billion, up from $1.53 billion in Q2 2025; TAVR sales were $1.26 billion, up 11.3%.
GAAP diluted EPS was $0.42 versus $0.56 a year earlier, including a $188.2 million valuation allowance against deferred tax assets.
Full-year 2026 sales growth guidance was raised to 10% to 11% from 9% to 11%; adjusted EPS guidance of $2.95 to $3.05 was reaffirmed.
For Q3 2026, Edwards projects total sales of $1.63 billion to $1.71 billion and adjusted EPS of $0.71 to $0.77.
At its May 7, 2026 annual meeting, Edwards Lifesciences stockholders approved an amendment to the Long-Term Stock Incentive Compensation Program that adds 7,000,000 shares, bringing the total share limit to 341,500,000. Stockholders also elected all nine director nominees and approved the advisory vote on named executive officer compensation and the auditor ratification.
Share limit under the Long-Term Stock Program rises by 7,000,000 shares to 341,500,000 shares.
Stockholder approval of the amended program: 456,675,201 for and 19,210,539 against.
All nine director nominees were elected, including David T. Feinberg, MD, and Bernard J. Zovighian.
Advisory executive pay proposal passed with 424,961,639 for and 50,924,101 against.
Edwards Lifesciences said on May 4, 2026 that Theodora Mistras, currently CFO of Viatris, will become corporate vice president and chief financial officer effective May 29, 2026, succeeding Scott Ullem, who has held the role since 2014. The Offer Letter sets a $925,000 base salary, a $2,013,000 sign-on bonus, and an $8,000,000 initial RSU grant, with a $4,500,000 target fiscal 2026 annual equity award, which shareholders can use to gauge the cost of the leadership change.
Mistras, age 44, has been CFO of Viatris since March 1, 2024; previously a managing director at Citigroup and Goldman Sachs healthcare investment banking.
Offer Letter dated May 2, 2026: $925,000 base salary and target annual bonus of not less than 100% of base salary, plus a $2,013,000 sign-on bonus.
Initial RSU award with a grant date value of $8,000,000, vesting 43.75%, 50% and 6.25% on the first, second and third anniversaries of her start date.
Scott Ullem announced his planned transition in October; the press release says he will continue as a strategic advisor in the months ahead.
Edwards Lifesciences reported first-quarter 2026 sales of $1.65 billion, up 16.7% from a year earlier, and GAAP diluted EPS of $0.66. The company raised its full-year 2026 sales growth guidance to 9% to 11% and the midpoint of its adjusted EPS guidance, and it completed a $500 million accelerated share repurchase.
Q1 sales grew 16.7% to $1.65 billion (12.7% on a constant currency basis); TAVR sales were $1.20 billion and TMTT sales were $173 million.
Q1 GAAP diluted EPS was $0.66 versus $0.61 a year earlier; adjusted EPS was $0.78 versus $0.64.
Full-year 2026 sales growth guidance raised to 9% to 11% from 8% to 10%; adjusted EPS guidance range is $2.95 to $3.05 versus $2.90 to $3.05 previously.
The company completed a $500 million accelerated share repurchase and has about $1.5 billion remaining under its authorization.
Edwards Lifesciences reported fourth-quarter 2025 net sales of $1.57 billion, up 13.3% from a year earlier, with TAVR sales up 12.0% and TMTT sales up more than 40%. Profit fell sharply on a GAAP basis: net income from continuing operations was $64.2 million, or $0.11 per diluted share, versus $345.0 million, or $0.58, a year earlier, after a $208.6 million litigation charge and a $99.8 million impairment on its JenaValve investment. The company said it has increased confidence in its 2026 outlook, including adjusted EPS of $2.90 to $3.05.
Q4 2025 net sales $1.57 billion, up 13.3% (11.6% constant currency); adjusted EPS $0.58 versus $0.59 a year earlier
GAAP diluted EPS from continuing operations $0.11, versus $0.58 in Q4 2024, reflecting $208.6 million in intellectual property and litigation expenses and a $99.8 million impairment loss
2026 guidance: constant currency sales growth of 8% to 10% and adjusted EPS of $2.90 to $3.05, with management citing increased confidence
Q1 2026 outlook: total sales of $1.55 billion to $1.63 billion and adjusted EPS of $0.70 to $0.76
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Edwards Lifesciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →